Oncocyte Corporation — FY2023 Form 10-K
Reporting period: Year ended December 31, 2023; filed April 15, 2024. The filing is for Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company—not “Insight Molecular Diagnostics Inc.”
Business context and reporting period
Oncocyte is developing and commercializing molecular tests in oncology and transplantation: DetermaIO (immunotherapy response), DetermaCNI (cancer therapy monitoring), and VitaGraft (transplant monitoring). Pharma Services provided nearly all 2023 revenue. In February 2023, Oncocyte sold 70% of Razor Genomics and transferred DetermaRx and its related assets and liabilities; it retained approximately 30%. Razor is reported as discontinued operations.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $1.503 million | $0.958 million |
| Gross profit (loss) | $0.413 million; 27.5% margin | $(0.018) million |
| Operating loss | $(25.136) million | $(17.997) million |
| Loss from continuing operations | $(24.855) million | $(18.612) million |
| Net loss | $(27.781) million | $(72.902) million |
| Net cash used in operating activities | $(23.325) million | $(45.568) million |
| Cash and cash equivalents at year-end | $9.432 million | $19.993 million |
Research and development expense was $9.294 million, sales and marketing $2.795 million, and general and administrative expense $11.182 million. Accumulated deficit was $289.9 million. Year-end total assets were $74.892 million, total liabilities $49.298 million, and shareholders’ equity $20.468 million. Restricted cash of $1.7 million was held for a lease letter of credit.
There was no outstanding bank loan at year-end. Operating lease liabilities were $2.730 million. Contingent consideration liabilities totaled $39.9 million, including $37.86 million related to Chronix and $2.04 million related to Insight. Series A redeemable convertible preferred stock had a $5.126 million carrying amount and $5.296 million liquidation preference.
Material changes versus FY2022
- Revenue rose 57%, primarily from increased Pharma Services contracts; Pharma Services accounted for $1.467 million, or 98% of revenue. Three customers represented 85% of revenue, creating significant concentration risk.
- Continuing-operations loss widened by $6.243 million, despite lower G&A, as R&D and sales and marketing costs increased and 2023 included asset impairment and disposal charges.
- Net loss improved by $45.121 million, largely because FY2022 included $54.290 million of discontinued-operations losses and an $18.684 million goodwill impairment. The 2023 loss included $2.926 million from discontinued operations.
- The fair-value gain on contingent consideration was $5.762 million in 2023, compared with $31.019 million in 2022; these noncash gains materially affect reported operating results.
- Cash used in operations declined to $23.325 million from $45.568 million. Financing provided $12.186 million in 2023, mainly from common stock issuance; cash and cash equivalents fell by year-end.
- Oncocyte recorded $5.0 million of DetermaIO in-process R&D impairment and $1.8 million of leasehold-improvement impairment, plus $1.283 million loss on disposal and held-for-sale assets.
The 2022 comparative financial statements were retrospectively adjusted for the 1-for-20 reverse stock split. The 2023 auditor audited the 2023 statements and the split adjustment, but did not audit the 2022 statements as a whole.
Outlook, risks and unusual items
- Going concern: Management and the auditor state that substantial doubt exists about the company’s ability to continue as a going concern for at least one year after issuance. Oncocyte expects continued operating losses and negative cash flows and says further financing is required; planned financing and cost reductions are not considered probable enough to alleviate the doubt.
- Subsequent financing: A private placement closed April 15, 2024, with gross proceeds of approximately $15.8 million before fees. The company said approximately $5.4 million would be used to redeem the remaining Series A preferred stock. The placement included 5,076,900 common shares and pre-funded warrants for up to 342,888 shares, implying substantial potential dilution.
- Commercialization: VitaGraft Kidney received a positive MolDx coverage decision in August 2023 and became available to order in January 2024. DetermaIO was still being developed for clinical use; management’s stated goal was availability later in 2024. DetermaCNI also remained under development. No quantified revenue or earnings guidance was provided.
- Management commentary: Management expects general operating expenses to remain flat while it manages cash, but anticipates continued R&D and commercialization spending. It may use partnerships, licensing, and distributors to reduce capital requirements.
- Regulatory and reimbursement risk: Medicare and commercial coverage and adequate reimbursement are uncertain. The FDA had proposed a phased increase in oversight of laboratory-developed tests; final requirements and their application to Oncocyte’s tests remained uncertain in the filing.
- Other notable events: A 10-year Bio-Rad collaboration was signed in April 2024 for research-use and IVD transplant kits. The company also disclosed high customer concentration, potential dilution, acquisition-related contingent payments, and a prior material weakness in financial reporting controls that management said was remediated in 2023.
Important facts for investors to verify
- Cash runway after the April 2024 financing, redemption of preferred stock, and ongoing operating cash use; assess whether additional financing may be needed.
- Terms and potential dilution from the April 2024 common-share and pre-funded-warrant issuance, alongside outstanding warrants, options, and preferred-stock obligations.
- Commercial orders, revenue, collections, and reimbursement progress for VitaGraft Kidney and the development and launch status of DetermaIO and DetermaCNI.
- Reliance on three Pharma Services customers for 85% of revenue and the sustainability of their contracts.
- Contingent consideration assumptions and the potential for future cash or share payments; the $39.9 million recorded liability depends on management estimates and milestones or future revenues.
- Effects of final FDA LDT rules and payer decisions on test availability, approval requirements, reimbursement, and commercialization costs.